Viking Therapeutics VKTX Proceeds from disposition of marketable securities and other investments
Proceeds from disposition of marketable securities and other investments at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's proceeds from disposition of marketable securities and other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's proceeds from disposition of marketable securities and other investments?
- Viking Therapeutics (VKTX) reported proceeds from disposition of marketable securities and other investments of $126.63M in Q1 2026.
- How has Viking Therapeutics's proceeds from disposition of marketable securities and other investments changed year-over-year?
- Viking Therapeutics's proceeds from disposition of marketable securities and other investments decreased by 57.2% year-over-year, from $295.86M to $126.63M.
- What is the long-term trend for Viking Therapeutics's proceeds from disposition of marketable securities and other investments?
- Over 4 years (2021 to 2025), Viking Therapeutics's proceeds from disposition of marketable securities and other investments has grown at a 38.6% compound annual growth rate (CAGR), from $205.98M to $759.43M.